CDKN2A and central nervous system cancer: Philip et al. (2018) utilized an RCAS-Ntv-a system to create an IDH1 mutant glioma model by expressing the IDH1-R132H oncoprotein and platelet derived growth factor receptor A (PDGFRA), and simultaneously silencing CDKN2A, alpha thalassemia/mental retardation syndrome x-linked (ATRX), and PTEN [170].